About 412,473 results

Dermatologists address cultural competence and unconscious biases in the specialty
Thomas R. Collins

Jan 30th, 2023 - ORLANDO – When he was applying for residency, Omar N. Qutub, MD, eagerly arrived at his first interview of the day.

Two AI optical diagnosis systems appear clinically comparable for small colorectal polyps
Carolyn Crist

Jan 30th, 2023 - In a head-to-head comparison, two commercially available computer-aided diagnosis systems appeared clinically equivalent for the optical diagnosis of small colorectal polyps, according to a research letter published in Gastroenterology. For the optical diagnosis of diminutive colorectal polyps, the comparable performances of both CAD-EYE (Fujifilm Co.

JAK Inhibitor Improves Symptoms, Anemia in Myelofibrosis

Jan 30th, 2023 - Myelofibrosis treatment with the Janus kinase (JAK) inhibitor momelotinib resulted in clinically significant improvements in symptoms and spleen response compared with danazol for symptomatic, JAK inhibitor-exposed patients with anemia and intermediate- or high-risk disease, the phase III MOMENTUM trial showed. A significantly greater proportion of patients in the momelotinib group reported a ≥...

Commentary: Early Diagnosis of PsA, February 2023
Vinod Chandran, MBBS, MD, DM, PhD

Jan 30th, 2023 - Vinod Chandran, MBBS, MD, DM, PhD Most patients develop psoriatic arthritis (PsA) after the onset of cutaneous psoriasis. The path toward long-term remission of PsA may be by early diagnosis and effective treatment prior to the onset of joint damage.

Cardiometabolic Risk With Autism: Vigilance Urged

Jan 30th, 2023 - People with autism had an elevated risk of cardiometabolic conditions across several dozen studies, researchers confirmed in a meta-analysis. Among children and adults in the analyzed studies, autism was associated with greater likelihood of concomitant: Yet, there was no significantly associated increased risk of hypertension and stroke with autism across all age groups, according to investiga...

Early Return to School After Concussion Linked to Lower Symptom Burden
Clinical Advisor

Jan 30th, 2023 - Children with a concussion may no longer have to sit quietly in a dark room for days. New research suggests that prolonged absence from school and other activities may hinder recovery from a concussion. Returning to school earlier than previously recommended may be associated with lower symptom burden, leading to a faster recovery, according to an published online in JAMA Network Open. The anal...

Study: Diminished COVID Vaccine Response in Lupus

Jan 30th, 2023 - Patients with systemic lupus erythematosus (SLE) showed reduced antibody responses following COVID-19 vaccination, with drugs for the condition such as belimumab (Benlysta) and mycophenolate mofetil (MMF) likely to blame, researchers said. Immunoglobulin G (IgG) titers measured 2 weeks after the second dose of mRNA COVID vaccines were lower by about 20% among 342 lupus patients compared with th...

Supervised Exercise Keeps Diabetes at Bay a Decade Later

Jan 30th, 2023 - Supervised moderate and vigorous aerobic activity helped stave off type 2 diabetes in at-risk individuals with central obesity and nonalcoholic fatty liver disease, according to 10-year follow-up of a randomized trial from China. Compared with adults who did not exercise, the risk of diabetes was reduced by 49% in the vigorous exercise group (relative risk [RR] 0.51, 95% CI 0.27-0.94, P=0.01) a...

Enriched ICU Nutrition Strategy Spoiled in Randomized Trial

Jan 30th, 2023 - Higher protein doses did not improve critically ill patient outcomes, and may even be detrimental to patients with high organ failure and acute kidney injury, the EFFORT trial found. In nutritionally high-risk adults undergoing mechanical ventilation, alive hospital discharge for those who received higher doses of protein reached 46.1% by 60 days after randomization, compared with the 50.2% rat...

Woman Seeks Answers After 3 Years of Painful Genital Ulcers

Jan 30th, 2023 - A woman in her late 40s presented with painful ulcers in her groin and armpits that hadn't healed in 3 years, an Indian group reported in JAMA Dermatology. The woman explained that when the sores first appeared, they were just itchy, oozing, reddish bumps; over time, they worsened to form painful, pus-filled oozing ulcers. She had been treated with numerous courses of antibiotics, antifungals, ...

Research Letter - Orthopoxvirus Infections in Rodents, Nigeria, 2018-2019

Research Letter — Orthopoxvirus Infections in Rodents, Nigeria, 2018–2019

Overall survival improved with chemotherapy in ER-negative/HER2-negative, T1abN0 BC

Jan 27th, 2023 - Key clinical point: Treatment with adjuvant chemotherapy significantly improved overall survival (OS) outcomes in patients with estrogen receptor-negative (ER−)/human epidermal growth factor receptor 2-negative (HER2−), T1abN0 breast cancer (BC). Major finding: After a median follow-up of 7.

Addition of atezolizumab to carboplatin+paclitaxel improves pCR in stage II-III TNBC

Jan 27th, 2023 - Key clinical point: Addition of atezolizumab to carboplatin+paclitaxel in the neoadjuvant setting improved the pathological complete response (pCR) rate in patients with stage II-III triple-negative breast cancer (TNBC). Major finding: After a median follow-up of 6.

ER/PgR+ BC: Adjuvant exemestane+ovarian suppression reduces recurrence risk

Jan 27th, 2023 - Key clinical point: Exemestane plus ovarian function suppression (OFS) led to a greater reduction in recurrence risk than tamoxifen+OFS in premenopausal women with estrogen or progesterone receptor-positive (ER/PgR+) early breast cancer (BC). Major finding: There was a significant improvement in 12-year disease-free survival (hazard ratio [ HR] 0.

Adding SBRT to sorafenib boosts survival in liver cancer
Roxanne Nelson, RN, BSN

Jan 27th, 2023 - SAN FRANCISCO – Adding stereotactic body radiation therapy (SBRT) to sorafenib produced better outcomes among patients with hepatocellular carcinoma (HCC) than sorafenib alone, according to new findings. The use of SBRT in this setting improved both overall survival and progression-free survival (PFS).

Are Boiled Peanuts the Answer to Peanut Allergy?
Clinical Advisor

Jan 27th, 2023 - Children with peanut allergies may benefit from an unusual oral immunotherapy regimen: boiled peanuts. Use of a boiled peanut regimen led to desensitization in 80% of children with peanut allergies enrolled in an open-label, phase 2 trial, which was published in Clinical & Experimental Allergy. Few children withdrew from the trial because of adverse events. “Small and increasing doses of boiled...

How Racial and Ethnic Disparities in Alzheimer Disease Affect Diagnosis, Quality of Care
Clinical Advisor

Jan 27th, 2023 - As researchers continue to seek insights to improve the understanding, prevention, and treatment of Alzheimer disease and related dementias (ADRD), a growing body of research highlights significant racial and ethnic disparities in various aspects of these diseases.1 “In Blacks and Hispanics, the prevalence of ADRD is 1.5 to 2 times higher compared to non-Hispanic Whites,” said Timothy S. Chang,...

Dr. Katerina Mastovska named AOAC INTERNATIONAL Deputy Executive Director and Chief Science Officer

Jan 27th, 2023 - AOAC INTERNATIONAL Executive Director David B. Schmidt is pleased to announce that Dr. Katerina (Kate) Mastovska has been named Deputy Executive Director and Chief Science Officer. Two current staff members, each with almost 20 years of experience at AOAC, Dawn L. Frazier and Deborah McKenzie, have been promoted to new roles at the nonprofit organization which ensures the safety and integrity o...

Testing a immunological drug as a new treatment for early type 1 diabetes

Jan 27th, 2023 - A large clinical study is now beginning on an approved drug for treating psoriasis. The drug will be tested on patients who were recently diagnosed with type 1 diabetes. The theory is that the drug could preserve the patient’s remaining insulin production. A large number of hospitals throughout Sweden are participating in this large project, which is funded by the Swedish Research Council withi...

Study shows FDA-approved TB regimen may not work against the deadliest form of TB due to multidrug-resistant strains

Jan 27th, 2023 - FOR IMMEDIATE RELEASE Findings from a Johns Hopkins Children’s Center study in animal models show that a U.S. Food and Drug Administration (FDA)-approved antibiotic regimen for multidrug-resistant (MDR) tuberculosis (TB) may not work for TB meningitis. Studies in a small number of people also provide evidence that a new combination of drugs is needed to develop effective treatments for TB menin...